Mesothelioma UK RCGP and the GP Continuity Gap

Mesothelioma UK, RCGP, and the GP Continuity Gap

Executive Summary

GP continuity — seeing the same family doctor consistently over time — is emerging as a measurable factor in how mesothelioma is recognized, referred, and managed within the National Health Service. A 2026 study in the British Journal of General Practice (BJGP) by Couchman and colleagues frames continuity of care as a priority issue for mesothelioma patients, arguing that the relationship between a patient and a single, familiar GP shapes how quickly asbestos-exposure history is captured, how urgently red-flag symptoms are escalated, and how well end-of-life planning is coordinated. The study lands against a backdrop of well-documented decline: in England, the share of patients who "always or almost always" saw or spoke to their preferred GP fell from 26% in 2018 to 16% in 2023, while the share who "never or almost never" did rose from 10% to 19% over the same period. Because mesothelioma is a disease of later life — over 70% of annual mesothelioma deaths in Great Britain now occur in people aged over 75, and UK incidence is highest at ages 80 to 84 — that system-wide decline runs straight through the age range in which mesothelioma overwhelmingly occurs. Separately, a systematic review of 22 studies found that higher continuity of care is associated with statistically significant reductions in mortality in 18 of them, and a large English study of patients aged 65 and older found, in its nested case-control arm, more than double the odds of an emergency hospital admission for patients with the least GP continuity compared to those with the most.

At a Glance

• A 2026 BJGP paper (Couchman et al.) sets out clinical, research, and policy recommendations for GP continuity in mesothelioma care.
• In England, the share of patients who "always or almost always" saw or spoke to their preferred GP fell from 26% in 2018 to 16% in 2023.
• Over the same period, the share who "never or almost never" saw or spoke to their preferred GP nearly doubled, rising from 10% to 19%.
• A systematic review found 18 of 22 high-quality studies linked greater continuity of care to reduced mortality.
• In the nested case-control arm of an English study of patients aged 65 and older, those with the least continuity had roughly double the odds of an emergency hospital admission compared to patients with the most.
• Continuity is not one thing: a BMJ review separates relational, informational, and management continuity, and mesothelioma care draws on all three from different parts of the NHS.
• NICE guideline NG12 lowers the symptom threshold for an urgent chest X-ray from two unexplained symptoms to just one if the patient has a history of asbestos exposure.
• With nivolumab plus ipilimumab now a first-line option, a GP is often the first clinician to see an immune-related adverse event.
• Mesothelioma UK's specialist nurses provide case-management continuity that can complement — but does not replace — a patient's relationship with their GP.

Key Facts

Metric	Finding
Saw preferred GP "always or almost always", England	26% in 2018, falling to 16% in 2023
Saw preferred GP "never or almost never", England	10% in 2018, rising to 19% in 2023
Continuity–mortality link	18 of 22 studies reviewed found reduced mortality with higher continuity
Continuity–emergency admission link	Odds ratio 2.32 (95% CI, 1.48–3.63) for least vs. most continuity — nested case-control arm, appointed-GP index; the prospective cohort arm of the same study gave a non-significant hazard ratio of 2.27
NICE NG12 asbestos threshold	1+ unexplained symptom + asbestos exposure history triggers urgent CXR (vs. 2+ symptoms without exposure)
Typical presenting symptoms	Breathlessness and chest pain, usually with a pleural effusion
First-line immunotherapy standard	Nivolumab plus ipilimumab (CheckMate 743)

The Couchman et al. (2026) BJGP Framework

The anchor study behind this analysis — Couchman, Ejegi-Memeh, Mitchell, and colleagues, published in the British Journal of General Practice in 2026 — makes the case that continuity of care deserves the same structured attention in mesothelioma pathways that it already receives in chronic disease management. The paper sets out recommendations across three domains: clinical practice (embedding continuity as an explicit goal in mesothelioma follow-up), research (validating continuity measurement tools in mesothelioma-specific cohorts, which the authors note has not yet been done), and policy (asking the Royal College of General Practitioners, NHS England, NICE, and Integrated Care Boards to formalize the GP's role across the mesothelioma care pathway).

Because the paper was published in mid-2026, its full text carries a standard journal embargo period, so specific line-by-line recommendations beyond the study's stated three-domain framework are not yet independently reproducible here. What is confirmed is the paper's existence, authorship, and general framing, drawn from the publication record and its supporting literature.

What "Continuity of Care" Actually Measures

Continuity of care is not a single concept. A widely cited multidisciplinary review by Haggerty and colleagues in the BMJ describes it as three related but distinct dimensions:

• Relational continuity — an ongoing therapeutic relationship between a patient and one or more providers over time.
• Informational continuity — the use of information from past events and circumstances to make current care appropriate for each patient.
• Management continuity — a consistent and coherent approach to managing a health condition that responds to a patient's changing needs.

For mesothelioma, relational continuity typically sits with the patient's GP, while management continuity is often anchored by a Mesothelioma UK clinical nurse specialist (CNS) — a model in which the two roles are complementary rather than redundant. One of the most commonly used tools for quantifying continuity is the Bice-Boxerman index, a measure originally developed in the 1970s and still used in current continuity research, including the emergency-admissions studies discussed below.

Why GP Continuity Is Declining

The decline in GP continuity is not specific to mesothelioma — it reflects a system-wide trend in NHS general practice. Analysis of the NHS GP Patient Survey found that the proportion of patients who "always or almost always" saw or spoke to their preferred GP fell from 26% in 2018 to 16% in 2023. The mirror-image measure moved in step: the proportion answering "never or almost never" rose from 10% to 19% across the same six surveys. Two cautions belong with those figures. The 2018 survey reworded the question, so the series is not directly comparable with the 42%-to-33% decline recorded between 2012 and 2017; and the 2025 survey changed it again, to ask about a preferred healthcare professional rather than a preferred GP, which is why the series stops at 2023 here.

The published series is not broken down by age or sex, so the decline cannot be attributed to older patients specifically on this evidence. What can be said is that the two populations overlap: mesothelioma in the UK is a disease of later life. The Health and Safety Executive reports that over 70% of annual mesothelioma deaths in Great Britain now occur in people aged over 75, and Cancer Research UK puts peak incidence at ages 80 to 84, where around one in five new UK cases is diagnosed. The continuity decline is measured across all NHS patients; the mesothelioma population sits at the older end of it.

Evidence Linking Continuity to Outcomes

Mortality

A systematic review by Pereira Gray and colleagues, published in BMJ Open in 2018, examined 22 high-quality studies on continuity of care and found that 18 of them (just over 80%) reported statistically significant reductions in mortality associated with higher continuity, an effect observed across both generalist and specialist care settings and multiple countries. For a disease with a median survival typically measured in months, the mechanisms proposed — earlier symptom escalation, better advance care planning, and improved concordance with palliative treatment — are directly relevant to how mesothelioma patients experience their remaining time.

Emergency Admissions

Two English studies, both using large routinely collected datasets, found a consistent relationship between lower continuity and higher rates of unplanned hospital admission. A Health Foundation analysis by Barker, Steventon, and Deeny in the BMJ found that greater continuity of care in general practice was associated with fewer hospital admissions for ambulatory-care-sensitive conditions — the kinds of conditions that, in principle, should be manageable without a hospital stay if primary care catches problems early. A companion analysis by Tammes, Purdy, Salisbury, and colleagues, published in the Annals of Family Medicine, analyzed records from 10,000 patients aged 65 and older across 297 English practices using two designs at once. In the prospective cohort arm, measured with the Bice-Boxerman index, the inverse relationship between continuity and admission risk was graded but not statistically significant, with a hazard ratio of 2.27 (95% CI, 1.37–3.76) for those experiencing the least continuity. In the retrospective nested case-control arm, using the appointed-GP index, the odds ratio for those experiencing the least continuity was 2.32 (95% CI, 1.48–3.63) relative to those experiencing the most. The widely quoted "double the odds" figure comes from that second arm, and the distinction matters: the study's authors concluded that discontinuity might contribute to unplanned admissions, not that it demonstrably causes them. Neither study looked specifically at mesothelioma patients, but the age group studied overlaps heavily with the mesothelioma-diagnosis demographic.

Recognizing Mesothelioma in Primary Care

Mesothelioma's presenting symptoms are frequently mistaken for more common respiratory conditions, which is one reason continuity and a GP's cumulative knowledge of a patient's occupational history matter. A 2005 Lancet review by Robinson, Musk, and Lake describes the typical presentation as breathlessness and chest pain accompanied by a pleural effusion. Because these symptoms overlap with far more common conditions, a documented history of asbestos exposure is often the detail that changes a GP's index of suspicion — and that history is more likely to surface, and be acted on promptly, when a patient sees a doctor who already knows them.

NICE guideline NG12 ("Suspected cancer: recognition and referral") builds asbestos exposure directly into its referral criteria. Under NG12, patients aged 40 or older are offered an urgent, direct-access chest X-ray if they have two or more unexplained symptoms from a defined list (cough, fatigue, shortness of breath, chest pain, weight loss, or appetite loss) — but the threshold drops to just one such symptom if the patient has a documented history of asbestos exposure. This makes a GP's awareness of a patient's occupational or environmental exposure history a direct, guideline-level input into how quickly a chest X-ray is ordered.

It's worth noting for clarity that NICE guideline NG122 covers lung cancer diagnosis and management generally and does not specifically address mesothelioma; there is no standalone current NICE guideline dedicated exclusively to mesothelioma diagnosis and management. Mesothelioma patients are managed operationally under the lung-cancer multidisciplinary-team framework, in combination with Mesothelioma UK's specialist nursing pathways.

Immunotherapy and the GP's Monitoring Role

The introduction of first-line immunotherapy has added a new dimension to primary care's role in mesothelioma management. The CheckMate 743 trial, published in The Lancet in 2021, established nivolumab plus ipilimumab as a first-line treatment option for unresectable malignant pleural mesothelioma, showing an overall survival benefit compared to standard chemotherapy. Immune checkpoint inhibitors carry a distinct side-effect profile — immune-related adverse events (irAEs) affecting the skin, gut, endocrine system, lungs, or other organs — that can present initially through primary care rather than the treating oncology center. A GP who already knows a patient's baseline health status is better positioned to distinguish a new irAE from an unrelated illness, which is one of the practical arguments the continuity literature makes for keeping mesothelioma patients anchored to a consistent primary-care relationship even while under specialist oncology management.

Palliative Care Timing

Mesothelioma's prognosis means palliative care planning conversations often need to begin close to diagnosis rather than late in the disease course. The Gold Standards Framework (GSF), a widely used UK approach to identifying patients who should be considered for a palliative care register, uses a "surprise question" — would the clinical team be surprised if the patient died within the next 12 months? Given mesothelioma's typical prognosis, most newly diagnosed patients meet this threshold, which is one reason the disease is often used as a teaching example for early palliative-care integration.

Separately, research on end-of-life priorities — including a widely cited study by Steinhauser and colleagues published in JAMA — found that patients, families, and physicians consistently rank being known and understood by their care team, having pain and symptoms controlled, and maintaining a sense of control as top priorities near the end of life. A consistent GP relationship supports several of these priorities directly, particularly the sense of being known rather than treated as an unfamiliar case at each visit.

The Mesothelioma UK and GP Relationship

Mesothelioma UK, the charity dedicated to supporting mesothelioma patients and families, provides specialist clinical nurse specialists (CNS) who act as a case-management anchor throughout diagnosis, treatment, and end-of-life care. The Couchman et al. framework treats the CNS role and the GP relationship as complementary rather than overlapping: the CNS provides continuity of disease-specific management and coordination with the oncology team, while the GP provides the longitudinal, whole-person relational continuity that predates the diagnosis and continues alongside it. Where this model breaks down — for example, when a patient cannot see the same GP consistently — both the specialist literature and the Couchman et al. paper suggest that some of the mortality and hospitalization benefits associated with continuity may be attenuated, though this has not yet been directly measured in a mesothelioma-specific cohort.

Frequently Asked Questions

Does seeing the same GP actually change mesothelioma outcomes?

Direct mesothelioma-specific trial evidence does not yet exist — the Couchman et al. 2026 paper itself identifies this as a research gap. However, the broader continuity-of-care literature, including a systematic review of 22 studies, found that higher continuity is associated with reduced mortality in the large majority of studies reviewed, and separate English research found roughly double the odds of emergency hospital admission for patients with the least continuity — in the nested case-control arm of that study; its prospective cohort arm pointed the same direction but did not reach statistical significance.

What symptoms should prompt an asbestos-exposure conversation with a GP?

Persistent breathlessness and chest pain, often with fluid on the lung, are the typical presenting symptoms of pleural mesothelioma. Anyone aged 40 or older with one or more of these symptoms and a history of asbestos exposure — through work in shipbuilding, construction, insulation, or related industries — meets the criteria under NICE guideline NG12 for an urgent chest X-ray.

Is there a specific NICE guideline for mesothelioma?

No standalone current NICE guideline covers mesothelioma diagnosis and management exclusively. NICE NG12 sets referral criteria that specifically name asbestos exposure and mesothelioma, and NICE technology appraisal TA135 addresses first-line chemotherapy; beyond that, mesothelioma patients are managed under the general lung-cancer multidisciplinary-team framework.

External Links

• Danziger & De Llano — mesothelioma attorneys, case evaluations for asbestos-exposed workers and families
• Mesothelioma.net — patient information and support resources
• Mesothelioma UK — the UK charity providing specialist clinical nurse support

Related Pages

• Mesothelioma Symptoms — full symptom guide by type and stage
• Mesothelioma Quick Facts — key statistics at a glance
• Immunotherapy for Mesothelioma — checkpoint inhibitor treatment overview
• Mesothelioma Diagnosis and Staging — diagnostic process and staging systems
• Occupational Exposure Index — asbestos-exposed occupations reference